Prescient Therapeutics Limited (ASX:PTX)
Industry Group : Pharmaceuticals, Biotechnology & Life Sciences | Industry Group Name : Biotechnology
Market Price : AUD 0.250.015 (6.383%)
(as on 2021-10-24 09:56:05)
(as on 2021-10-24 09:56:05)
|Previous Close||Open||Close*||Day Range||52 WEEK HIGH LOW|
|0.235||0.24||0.25||0.24L 0.25 H||0.054L 0.305 H|
|52 W H/L||0.305/0.054|
|NPAT After Abnormal Items||-4.149 M|
|Total Revenue||1.235 M|
|Cash and Cash Equivalents||16.098 M|
|Market Cap||161.148 M|
|Price/Gross Cash Flow||-53.37|
|Dividend Yield Excluding Special||0.00%|
|Ending Shares||641.053 M||52-Week Range||0.054-0.305|
|Net Profit Margin (%)||--|
|Gross Cash Flows Per Share||-0.00|
|Gross DPS (AUD)||0|
|Gross Dividend Yield (Annualized)||0.00%|
|Net Tangible Asset (NTA)||0.03|
|Sales Per Share||0.00|
|Book Value Per Share||0.03|
ASX-listed clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX) is focused on the development of revolutionary personalised therapies for challenging cancers having unmet medical need. Prescient’s key programs are universal CAR-T and targeted therapies. Both approaches seek to improve patient outcomes and develop new tools for clinicians to combat cancer.
Notably, Prescient Therapeutics is backed by a leading team of global cancer specialists who hold extensive experience in advancing new cancer therapies.
Prescient has a comprehensive product pipeline of personalised cancer treatments for several different cancers:
Source: PTX Website
CAR-T therapies include OmniCAR and Cell Therapy Enhancement Programs
OmniCAR program: Prescient’s universal CAR-T platform, OmniCAR, employs technology that is licensed from the University of Pennsylvania and Oxford University.
PTX’s pioneering OmniCAR program will allow unprecedented control and flexibility over the current generation CAR-T methods.
Interestingly, Prescient has announced three next-generation OmniCAR programs for AML, Her2+ solid tumours and glioblastoma multiforme (GBM). PTX has also entered into a new research agreement with Peter MacCallum Cancer Centre to advance its CAR-T programs.
Cell Therapy Enhancements (CTE): Prescient’s CTE programs are progressing well with initial promising findings. Two CTE programs are underway with Peter MacCallum and Carina Biotech, respectively.
Targeted Therapies - PTX-100 and PTX-200
PTX-100 is a first in class RhoA inhibitor and can block GGT-1 (geranylgeranyl transferase-1), a crucial cancer growth enzyme.
PTX-200, a novel PH domain inhibitor, blocks Akt pathway. Akt plays a vital role in the development of numerous malignancies, including breast and ovarian cancer and leukemia.
Level 4, 100 Albert Road, SOUTH MELBOURNE, VIC, AUSTRALIA, 3205
(03) 9692 7222
|Ex-Dividend Date||Franking||DPS (AUD)||Dividend Yield|
|Event Type||Event Date||Event Year|
|Other Revenue||1.235 M||1.107 M||1.679 M||939,771||1.058 M|
|Total Revenue||1.235 M||1.107 M||1.679 M||939,771||1.058 M|
|Expenses||-5.439 M||-4.493 M||-5.545 M||-3.635 M||-3.792 M|
|EBITDA||-4.204 M||-3.386 M||-3.866 M||-2.695 M||-2.734 M|
|Depreciation and Amortization||-474||-904||0||-1,471||0|
|EBIT||-4.204 M||-3.387 M||-3.866 M||-2.697 M||-2.734 M|
|Pre Tax Profit||-4.149 M||-3.321 M||-3.797 M||-2.574 M||-2.568 M|
|Net Profit After Tax||-4.149 M||-3.321 M||-3.797 M||-2.574 M||-2.568 M|
|Net Abnormal Items||0||0||0||0||0|
|Reported Net Profit After Abnormal Items||-4.149 M||-3.321 M||-3.797 M||-2.574 M||-2.568 M|
|Ending Shares||641.053 M||394.261 M||394.261 M||215.726 M||215.1 M|
|Weighted Average Shares||611.805 M||394.261 M||244.545 M||215.222 M||213.785 M|
|EPS After Abnormal Items (cents)||-0.68||-0.84||-1.55||-1.2||-1.2|
|Total Current Assets||17.598 M||8.705 M||11.639 M||6.622 M||8.861 M|
|Total Non Current Assets||3.369 M||3.367 M||3.368 M||3.369 M||3.369 M|
|Total Assets||20.967 M||12.072 M||15.007 M||9.991 M||12.23 M|
|Total Current Liabilities||514,675||864,244||668,030||543,775||440,646|
|Total Non Current Liabilities||25,002||19,707||17,763||7,785||4,249|
|Net Assets||20.427 M||11.188 M||14.321 M||9.439 M||11.785 M|
|Net Operating Cash||-3.97 M||-2.317 M||-4.195 M||-2.149 M||-3.278 M|
|Net Invested Cash||-2,314||0||0||-1,522||-21,686|
|Net Financing Cash Flows||12.75 M||0||8.367 M||-635||1.221 M|
|Beginning Cash||7.357 M||9.64 M||5.486 M||7.645 M||9.754 M|
|End Cash Position||16.098 M||7.357 M||9.64 M||5.486 M||7.645 M|
|Exchange Rate Adjustments||-36,945||34,623||-17,478||-8,203||-28,921|
|Other Cash Adjustments||0||0||0||0||0|
|Ending Cash||16.098 M||7.357 M||9.64 M||5.486 M||7.645 M|
© Morningstar, Inc. 2021. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the market indices, commodities and regulatory news headlines, and other data or content contained herein to be accurate, complete, or timely, and nor shall they have any liability for its use or distribution. The data contained herein: (1) is proprietary to Morningstar and/or its affiliates (collectively, “Morningstar”) and/or their content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Our publications, ratings and products should be viewed as an additional investment resource, and not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your financial situation, contact a professional financial adviser. Some material is copyrighted and published under licence from ASX Operations Pty. Ltd. ACN 004523782.